文献速递乳腺癌

顺铂联合维利帕尼或安慰剂治疗转移性三阴性乳腺癌和BRCA突变相关乳腺癌(S1416):一项随机、双盲、安慰剂对照的2期试验

Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial.
PubMed 文献 · Lancet Oncol · 2023-01-06

S1416是一项在美国154个中心开展的随机双盲安慰剂对照2期试验,纳入320例可评估的转移性或复发性三阴性乳腺癌或胚系BRCA1/2相关乳腺癌患者,比较顺铂联合维利帕尼与顺铂联合安慰剂的疗效。在BRCA样亚组中,联合维利帕尼显著改善无进展生存期(中位5.9 vs 4.2个月,HR 0.57,P=0.010);在胚系BRCA1/2突变组和非BRCA样组中无显著差异。

要点

  • BRCA样转移性三阴性乳腺癌患者中,顺铂联合维利帕尼较顺铂联合安慰剂显著改善无进展生存期(HR 0.57)。
  • 胚系BRCA1/2突变组和非BRCA样组中,联合维利帕尼与安慰剂的无进展生存期无显著差异。
  • 联合维利帕尼组3级及以上中性粒细胞减少(46% vs 20%)等血液学不良事件发生率高于安慰剂组。

核心结论

  • 在BRCA样转移性三阴性乳腺癌患者中,顺铂联合维利帕尼较顺铂联合安慰剂显著改善无进展生存期;在非BRCA样患者中未观察到显著改善。
  • 作者认为,PARP抑制剂联合铂类化疗应在BRCA样三阴性乳腺癌中进一步探索。

研究设计与样本

  • S1416是一项在美国154个社区和学术临床中心开展的随机、双盲、安慰剂对照、2期试验,注册号NCT02595905。
  • 纳入年龄≥18岁、ECOG体能状态0-2分、转移性或复发性三阴性乳腺癌或胚系BRCA1/2相关乳腺癌、且转移性疾病接受过至多一线化疗的患者。
  • 患者按1:1随机分配至顺铂(75 mg/m2,第1天静脉给药)联合维利帕尼或匹配安慰剂(300 mg口服,每日两次,第1-14天),21天为一周期。
  • 随机化后经中心检测将胚系BRCA1/2野生型患者按预设生物标志物面板分为BRCA样和非BRCA样表型组;BRCA样状态基于以下至少一项:基因组不稳定评分≥42、体细胞BRCA1/2突变、BRCA1启动子甲基化或非BRCA1/2同源重组修复胚系突变。
  • 主要终点为研究者评估的无进展生存期,在三个预设生物标志物组中分别分析,每组有预设的α值;疗效分析采用意向治疗人群,安全性分析纳入至少接受一剂维利帕尼或安慰剂的患者。

主要发现

  • 2016年7月7日至2019年6月15日共入组并随机分配335例患者,其中320例(顺铂联合维利帕尼组162例,均为女性;顺铂联合安慰剂组158例,157例女性和1例男性)符合疗效评估条件。
  • 247例患者被分入三个生物标志物组:胚系BRCA1/2突变组37例、BRCA样组101例、非BRCA样组109例;73例因生物标志物信息缺失未能分类。
  • 中位随访时间为11.1个月(IQR 5.6-20.8)。
  • 胚系BRCA1/2突变组:顺铂联合维利帕尼组中位无进展生存期6.2个月(95% CI 2.3-9.2),顺铂联合安慰剂组6.4个月(95% CI 4.3-8.2),HR 0.79(95% CI 0.38-1.67),log-rank P=0.54。
  • BRCA样组:顺铂联合维利帕尼组中位无进展生存期5.9个月(95% CI 4.3-7.8),顺铂联合安慰剂组4.2个月(95% CI 2.3-5.0),HR 0.57(95% CI 0.37-0.88),P=0.010。

临床怎么用

  • 作者认为,PARP抑制剂联合铂类化疗应在BRCA样三阴性乳腺癌中进一步探索。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Poly(ADP-ribose) polymerase (PARP) inhibitors are effective in germline BRCA1 or BRCA2 (BRCA1/2) mutation-associated metastatic breast cancer. However, studies evaluating PARP inhibitors plus platinum-based chemotherapy in germline BRCA1/2-wildtype triple-negative breast cancer are scarce. A large proportion of germline BRCA1/2-wildtype triple-negative breast cancer shows homologous recombination deficiency (HRD), resulting in a BRCA-like phenotype that might render sensitivity to PARP inhibitors. The S1416 trial assessed the efficacy of cisplatin combined with the PARP inhibitor veliparib in three predefined groups of metastatic breast cancer: germline BRCA1/2-mutated, BRCA-like, and non-BRCA-like. METHODS: S1416 was a randomised, double-blind, placebo-controlled, phase 2 trial conducted at 154 community and academic clinical sites across the USA. Eligible patients aged 18 years or older had metastatic or recurrent triple-negative breast cancer or germline BRCA1/2-associated metastatic or recurrent breast cancer, an Eastern Cooperative Oncology Group performance status of 0-2, and had received up to one line of chemotherapy for metastatic disease. Patients were randomly assigned (1:1) via the National Clinical Trials Network open interactive system with dynamic balancing on number of previous cytotoxic regimens for metastatic disease to receive intravenous cisplatin (75 mg/m2, day 1) combined with either veliparib or matching placebo (300 mg orally twice a day, days 1-14) on a 21-day cycle. Investigators, patients, and the sponsors were masked to treatment assignment; the study statisticians were unmasked. Central testing after ran domisation classified patients as having mutated or wildtype germline BRCA1/2. A biomarker panel established a priori was used to classify patients with wildtype germline BRCA1/2 into BRCA-like and non-BRCA-like phenotype groups, with BRCA-like status based on at least one of the biomarkers: genomic instability score (≥42), somatic BRCA1/2 mutations, BRCA1 promoter methylation, or non-BRCA1/2 homologous recombination repair germline mutations. The primary endpoint was investigator-assessed progression-free survival, analysed separately for the three predefined biomarker groups with a prespecified α value for each analysis. Efficacy analyses were done by intention to treat and included all eligible patients. Safety analyses of toxicities attributed to treatment included all patients who received at least one dose of veliparib or placebo. The study is ongoing and registered with ClinicalTrials.gov, NCT02595905. FINDINGS: Between July 7, 2016, and June 15, 2019, 335 patients were enrolled and randomly assigned. 320 patients (n=162 to cisplatin plus veliparib, all women; and n=158 to cisplatin plus placebo, 157 women and one man) were eligible for efficacy evaluation. 247 patients were classified into the three biomarker groups: germline BRCA1/2-mutated (n=37), BRCA-like (n=101), and non-BRCA-like (n=109). 73 patients could not be classified due to missing biomarker information. Median follow-up was 11·1 months (IQR 5·6-20·8). In the germline BRCA1/2-mutated group, median progression-free survival was 6·2 months (95% CI 2·3-9·2) in the cisplatin plus veliparib group and 6·4 months (4·3-8·2) in the cisplatin plus placebo group (HR 0·79 [95% CI 0·38-1·67]; log-rank p=0·54). In the BRCA-like group, median progression-free survival was 5·9 months (95% CI 4·3-7·8) in the cisplatin plus veliparib group versus 4·2 months (2·3-5·0) in the cisplatin plus placebo group (HR 0·57 [95% CI 0·37-0·88]; p=0·010). In the non-BRCA-like group, median progression-free survival was 4·0 months (95% CI 2·5-4·7) in the cisplatin plus veliparib group versus 3·0 months (2·2-4·4) in the cisplatin plus placebo group (HR 0·89 [95% CI 0·60-1·33]; p=0·57). The most common grade 3 or worse adverse events attributed to treatment were neutropenia (71 [46%] of 155 patients in the cisplatin plus veliparib group vs 29 [20%] of 147 in the cisplatin plus placebo group), leukopenia (42 [27%] vs 11 [7%]), anaemia (35 [23%] vs 12 [8%]), and thrombocytopenia (29 [19%] vs four [3%]). Serious adverse events attributed to treatment occurred in 48 (31%) patients in the cisplatin plus veliparib group and 53 (36%) patients in the cisplatin plus placebo group. Treatment-related adverse events led to death in one patient in the cisplatin plus veliparib group (sepsis) and one patient in the cisplatin plus placebo group (acute kidney injury due to cisplatin plus heart failure from previous doxorubicin exposure). INTERPRETATION: The addition of veliparib to cisplatin significantly improved progression-free survival in patients with BRCA-like metastatic triple-negative breast cancer, but not in patients with non-BRCA-like metastatic breast cancer. PARP inhibitors combined with platinum-based chemotherapy should be explored further in BRCA-like triple-negative breast cancer. FUNDING: National Cancer Institute and National Institute of General Medical Sciences (US National Institutes of Health); AbbVie; Myriad Genetics; the Biomarker, Imaging, and Quality of Life Studies Funding Program (awarded by the National Cancer Institute); and The University of Kansas Cancer Center.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Rodler E, Sharma P, Barlow WE, et al. Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2023. PMID: 36623515. doi:10.1016/S1470-2045(22)00739-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。